KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Share-based Compensation for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 24.79% year-over-year to $6.7 million, compared with a TTM value of $14.7 million through Dec 2025, down 53.54%, and an annual FY2025 reading of $14.7 million, down 53.54% over the prior year.
  • Share-based Compensation was $6.7 million for Q4 2025 at Aurinia Pharmaceuticals, up from $5.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.3 million in Q2 2023 and bottomed at -$3.4 million in Q1 2025.
  • Average Share-based Compensation over 5 years is $7.8 million, with a median of $8.1 million recorded in 2021.
  • The sharpest move saw Share-based Compensation soared 123.71% in 2021, then tumbled 159.42% in 2025.
  • Year by year, Share-based Compensation stood at $8.6 million in 2021, then fell by 19.53% to $6.9 million in 2022, then skyrocketed by 70.5% to $11.8 million in 2023, then decreased by 23.98% to $8.9 million in 2024, then dropped by 24.79% to $6.7 million in 2025.
  • Business Quant data shows Share-based Compensation for AUPH at $6.7 million in Q4 2025, $5.9 million in Q3 2025, and $5.4 million in Q2 2025.